Colossal Biosciences is now valued at over $10 billion and is working on ambitious projects to resurrect multiple long ...

Innovative synthetic biology techniques are revolutionizing microbiota-based therapies, enhancing microbial functions for ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Colossal Biosciences is working to bring back species like the woolly mammoth using CRISPR-Cas9 technology. The project aims to restore lost biodivers ...

The field of cancer research is rapidly evolving, with a growing focus on the intersection of cancer immunology, gene editing, and epigenetics. This ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Arkadios Wealth Advisors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

By 2025, innovations such as lab-on-a-chip technology, automation, and CRISPR-Cas9 gene editing are expected to enhance ...

Researchers uncover how the SiPRR37 gene regulates the flowering process of millet crops across regional climates, paving way ...